Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05244798 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sintilimab Plus NCT or NCRT Versus NCRT for ESCC

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 25, 2022 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Mar 1, 2022 to Nov 1, 2022v2 Show 8 more changesShow less
    • Enrollment target: 360 to 420
    • Interventions: Tislelizumab (Drug) to Chemotherapy (Drug), Sintilimab (Drug), radiotherapy (Radiation)
    • Eligibility criteria expanded, about 179 words
    • Secondary endpoints: 5 to 9
    • Study description expanded, about 38 words
    • Collaborators expanded, about 44 words
    • Study arms: 2 to 3
    • Study title expanded, about 1 word
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Comparative analysis of patients with resectable locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy combined sintilimab versus neoadjuvant chemoradiotherapy.
Trial Details
NCT Number NCT05244798
Lead Sponsor Sichuan Cancer Hospital and Research Institute
Collaborators: Peking University Cancer Hospital & Institute, Tianjin Medical University Cancer Institute and Hospital, Hebei Medical University Fourth Hospital, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, Anyang Tumor Hospital, Shantou Central Hospital, Innovent Biologics (Suzhou) Co. Ltd., GeneCast Biotechnology Co., Ltd.
Conditions
(from sponsor)		 Esophageal Squamous Cell Carcinoma
Related terms Esophageal Squamous Cell Carcinoma
Enrollment 420 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov